Zacks: Analysts Count on Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Will Announce Quarterly Gross sales of $114.67 Million

0
396

Wall Street brokers expect Tandem Diabetes Care, Inc. (NASDAQ: TNDM) to generate revenue of $ 114.67 million in the current fiscal quarter, according to Zacks. Four analysts have made estimates for Tandem Diabetes Care’s earnings, with the lowest revenue estimate being $ 111.00 million and the highest estimate being $ 123.78 million. Tandem Diabetes Care achieved sales of USD 97.93 million in the same quarter last year, which is a positive growth rate of 17.1% over the previous year. The company is expected to release its next results on Thursday April 29th.

According to Zacks, analysts expect Tandem Diabetes Care to report total annual sales of $ 564.30 million for the current fiscal year, with estimates ranging between $ 555.00 million and $ 573.81 million. For the next year, analysts expect the company to generate revenues of $ 666.74 million, with estimates ranging from $ 637.30 million to $ 690.70 million. Zacks Investment Research’s average revenue is based on a survey of sell-side analysts involved in Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ: TNDM) last released its quarterly earnings data on Tuesday, February 23rd. The medical device company reported earnings of $ 0.22 per share for the quarter, beating Zacks’ consensus estimate of $ 0.12 by $ 0.10. Tandem Diabetes Care had a negative net margin of 11.10% and a negative return on equity of 10.98%.

TNDM has been the subject of several research analyst reports. Raymond James raised its price target for Tandem Diabetes Care from $ 116.00 to $ 124.00 and rated the company “Outperform” in a report on Friday, November 6th. Wells Fargo & Company downgraded Tandem Diabetes Care from an “overweight” rating to a “balanced” rating and set a price target of $ 105.00 on the stock. in a report on Tuesday, December 15. SVB Leerink raised its price target for Tandem Diabetes Care from US $ 120.00 to US $ 130.00 and rated the company as “market performance” in a report on Friday, November 6th. Lake Street Capital raised its target price for Tandem Diabetes Care from USD 137.00 to USD 150.00 and gave the stock a “Buy” rating in a research note on Thursday, February 25th. Eventually, Zacks Investment Research cut Tandem Diabetes Care from a “buy” rating to a “hold” rating and set a price target of $ 101.00 for the company. in a research report on Monday. Five analysts have given the share a hold rating and nine have given it a buy rating. Tandem Diabetes Care has an average rating of “Buy” and a consensus target of $ 117.36.

(Display)

California is the largest market in the world for MJ and a company is about to open one of the largest facilities in the state. This could be the hottest game downstairs on MJ!

TNDM opened at $ 95.83 on Tuesday. Tandem Diabetes Care has a 52-week low of $ 43.69 and a 52-week high of $ 123.74. The company has a quick rate of 4.94, a current rate of 5.61, and a leverage ratio of 0.61. The company has a 50-day simple moving average of $ 96.82 and a 200-day simple moving average of $ 102.14. The company has a market cap of $ 5.84 billion, a P / E of -118.31, and a beta of 0.31.

In other news, director Kim D. Blickenstaff sold 9,150 shares in the company in a transaction dated Friday, December 11th. The stock was sold at an average price of $ 93.00 for a total transaction of $ 850,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this link. In addition, director Kim D. Blickenstaff sold 13,598 shares in the company on Tuesday, December 15. The stock sold at an average price of $ 92.48 for a total value of $ 1,257,543.04. The disclosure for this sale can be found here. In the past ninety days, insiders have sold 38,598 shares in the company, valued at $ 3,612,817. Insiders own 6.00% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares in the company. US Bancorp DE increased its stake in Tandem Diabetes Care by 16.4% in the fourth quarter. US Bancorp DE now owns 795 shares in the medical device company valued at $ 76,000 after purchasing an additional 112 shares last quarter. Manchester Financial Inc. increased its stake in Tandem Diabetes Care by 48.4% in the fourth quarter. Manchester Financial Inc. now owns 371 shares in the medical device company, valued at $ 35,000, after purchasing an additional 121 shares last quarter. Banque Cantonale Vaudoise increased its stake in Tandem Diabetes Care by 5.9% in the fourth quarter. Banque Cantonale Vaudoise now owns 2,929 shares in the medical device company valued at $ 281,000 after purchasing an additional 164 shares last quarter. Aperio Group LLC increased its stake in Tandem Diabetes Care by 5.9% in the third quarter. Aperio Group LLC now owns 3,442 shares in the medical device company valued at $ 391,000 after purchasing an additional 192 shares last quarter. Finally, WCM Investment Management LLC increased its stake in Tandem Diabetes Care by 0.3% in the fourth quarter. WCM Investment Management LLC now owns 72,108 shares in the medical device company valued at $ 6,899,000 after acquiring an additional 198 shares last quarter. 88.60% of the shares are owned by hedge funds and other institutional investors.

Tandem Diabetes Care company profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and markets a variety of products for people with insulin-dependent diabetes in the United States. The company’s flagship is the t: slim X2 insulin delivery system, a pump platform that includes the t: slim X2 pump, the disposable 300-unit insulin cartridge and an infusion set.

See also: Shares Outstanding

Get a Free Copy of Zacks Research Report on Tandem Diabetes Care (TNDM)

For more information on research offerings from Zacks Investment Research, please visit Zacks.com

Yield history and estimates for tandem diabetes care (NASDAQ: TNDM)

This instant message alert was generated through narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]

13 Shares Institutional investors won’t stop buying

University foundations, pension funds, sovereign wealth funds, hedge funds and other institutional investors invest money in a group of 13 elite stocks.

These institutional investors are not easily influenced by hot stocks that are popular with retail investors. You probably won’t see a Tesla or SnapChat in this group, as institutional investors know that these “popular kid” stocks almost always aren’t great investments. However, on this list you can find some excellent companies backed by real earnings and real fundamentals.

We had to go through every 13D and 13F filings that institutional investors filed with the SEC last quarter to identify these stocks. After reviewing more than 5,000 submissions, we identified 13 companies that institutional investors have still bought. Big money investors put hundreds of millions of dollars in these stocks.

Check out the “13 Stocks Institutional Investors Won’t Stop Buying”.